Dishman Carbogen Amcis Limited (DCAL) - Total Assets
Based on the latest financial reports, Dishman Carbogen Amcis Limited (DCAL) holds total assets worth Rs111.09 Billion INR (≈ $1.20 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Dishman Carbogen Amcis Limited (DCAL) shareholders funds for net asset value and shareholders' equity analysis.
Dishman Carbogen Amcis Limited - Total Assets Trend (2005–2025)
This chart illustrates how Dishman Carbogen Amcis Limited's total assets have evolved over time, based on quarterly financial data.
Dishman Carbogen Amcis Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Dishman Carbogen Amcis Limited's total assets of Rs111.09 Billion consist of 22.0% current assets and 78.0% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs100.00 Million | 5.1% |
| Accounts Receivable | Rs6.69 Billion | 6.7% |
| Inventory | Rs9.00 Billion | 9.0% |
| Property, Plant & Equipment | Rs31.71 Billion | 31.7% |
| Intangible Assets | Rs2.93 Billion | 2.9% |
| Goodwill | Rs40.54 Billion | 40.5% |
Asset Composition Trend (2005–2025)
This chart illustrates how Dishman Carbogen Amcis Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Dishman Carbogen Amcis Limited market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dishman Carbogen Amcis Limited's current assets represent 22.0% of total assets in 2025, a decrease from 57.5% in 2005.
- Cash Position: Cash and equivalents constituted 5.1% of total assets in 2025, up from 2.5% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 42.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is goodwill at 40.5% of total assets.
Dishman Carbogen Amcis Limited Competitors by Total Assets
Key competitors of Dishman Carbogen Amcis Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Dishman Carbogen Amcis Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.10 | 1.04 | 1.14 |
| Quick Ratio | 0.64 | 0.60 | 0.75 |
| Cash Ratio | 0.28 | 0.19 | 0.00 |
| Working Capital | Rs2.25 Billion | Rs773.10 Million | Rs2.15 Billion |
Dishman Carbogen Amcis Limited - Advanced Valuation Insights
This section examines the relationship between Dishman Carbogen Amcis Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.42 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 4.4% |
| Total Assets | Rs99.99 Billion |
| Market Capitalization | $310.59 Million USD |
Valuation Analysis
Below Book Valuation: The market values Dishman Carbogen Amcis Limited's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Dishman Carbogen Amcis Limited's assets grew by 4.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Dishman Carbogen Amcis Limited (2005–2025)
The table below shows the annual total assets of Dishman Carbogen Amcis Limited from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs99.99 Billion ≈ $1.08 Billion |
+4.36% |
| 2024-03-31 | Rs95.81 Billion ≈ $1.04 Billion |
+1.35% |
| 2023-03-31 | Rs94.53 Billion ≈ $1.02 Billion |
+9.45% |
| 2022-03-31 | Rs86.37 Billion ≈ $934.11 Million |
+3.24% |
| 2021-03-31 | Rs83.66 Billion ≈ $904.76 Million |
+2.03% |
| 2020-03-31 | Rs82.00 Billion ≈ $886.78 Million |
+11.89% |
| 2019-03-31 | Rs73.28 Billion ≈ $792.55 Million |
+2.12% |
| 2018-03-31 | Rs71.76 Billion ≈ $776.11 Million |
+8.84% |
| 2017-03-31 | Rs65.93 Billion ≈ $713.05 Million |
+121.22% |
| 2016-03-31 | Rs29.81 Billion ≈ $322.33 Million |
+5.96% |
| 2015-03-31 | Rs28.13 Billion ≈ $304.22 Million |
+9.07% |
| 2014-03-31 | Rs25.79 Billion ≈ $278.92 Million |
+11.41% |
| 2013-03-31 | Rs23.15 Billion ≈ $250.35 Million |
+2.93% |
| 2012-03-31 | Rs22.49 Billion ≈ $243.22 Million |
+8.00% |
| 2011-03-31 | Rs20.82 Billion ≈ $225.19 Million |
+16.18% |
| 2010-03-31 | Rs17.92 Billion ≈ $193.83 Million |
+6.11% |
| 2009-03-31 | Rs16.89 Billion ≈ $182.68 Million |
+14.94% |
| 2008-03-31 | Rs14.70 Billion ≈ $158.94 Million |
+26.60% |
| 2007-03-31 | Rs11.61 Billion ≈ $125.54 Million |
+94.91% |
| 2006-03-31 | Rs5.96 Billion ≈ $64.41 Million |
+84.86% |
| 2005-03-31 | Rs3.22 Billion ≈ $34.84 Million |
-- |
About Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organop… Read more